Atlas Discovery vs Isomorphic Labs
Side-by-side comparison of features, pricing, and ratings
At a glance
| Dimension | Atlas Discovery | Isomorphic Labs |
|---|---|---|
| Pricing | Contact-based | Contact-based (pharma partnerships) |
| Core Technology | ExpressionVAE foundation models for patient drug response from clinical data | AlphaFold-based predictive & generative AI for protein-ligand interactions |
| Business Model | Partnerships, YC-backed, target pharma R&D | Deep pharma collaborations (Novartis, J&J) |
| Validation | AUROC 0.76 for ustekinumab response, ICLR/ICML presentations | Nobel Prize-winning AlphaFold, $600M funding, J&J collaboration |
| Target User | Pharma scientists, trial designers, translational bioinformaticians | Large pharma companies for drug discovery programs |
| Latest News | ExpressionVAE paper (Jun 2026), clinical prediction model (Jun 2026) | Series B (Feb 2026), J&J collaboration (Jan 2026) |
Isomorphic Labs is the pick for large pharma seeking end-to-end AI drug discovery with AlphaFold prestige and massive funding. Atlas Discovery is better for organizations focused on de-risking clinical trials via patient response predictions. Choose based on your bottleneck: molecule design or clinical success prediction.
AI foundation models predicting patient drug response to de-risk clinical trials.
Visit Website
What real users say: Atlas Discovery vs Isomorphic Labs
Not marketing copy and not our opinion — a structured sweep of public discussion (reviews, forums, communities and video comments), showing what people praise and what they complain about for each tool.
Atlas Discovery
28 mentions across 3 sources · 37% positive — critical
Hacker News, YouTube, Lemmy
What users praise
- • Published AUROC of 0.76 predicting ustekinumab response from baseline biopsies.
- • ExpressionVAE outperforms continuous latent-variable baselines by 3–20x on distributional metrics.
- • Drug repurposing agent recovers dapagliflozin at rank 2 versus TxGNN's 4,388.
- • Backed by YCombinator, Pear, and Glasswing, indicating investor confidence.
What frustrates them
- • No public API or self-service interface; requires contacting company.
- • No independent community testing or user reviews to validate claims.
- • Research-grade tool, not plug-and-play; requires advanced bioinformatics skills.
- • Limited transparency on pricing and deployment infrastructure.
Researched Aug 16, 2026
Isomorphic Labs
48 mentions across 3 sources · 82% positive
Hacker News, YouTube, Lemmy
What users praise
- • Built on the Nobel-winning AlphaFold, giving it instant credibility in structural biology.
- • Drug Design Engine extends beyond structure to generative molecule design, promising novel chemistry.
- • Deep partnerships with Novartis and J&J, with potential billions in royalties.
- • Interdisciplinary team of top ML and drug discovery experts, ensuring depth of expertise.
What frustrates them
- • Not accessible to individual researchers or small biotech due to partnership model only.
- • Proprietary nature of parts of its tech limits community scrutiny and independent validation.
- • CASP16 results suggest AlphaFold 3-based models aren't always better than older methods for protein-ligand interactions.
- • No marketed drugs yet; outcomes remain uncertain with royalties tied to long timelines.
Researched Aug 18, 2026
Who should pick which
- Large pharma company seeking AI-driven drug discoveryPick: Isomorphic Labs
Isomorphic Labs offers a partnership model with AlphaFold-derived capabilities for protein-ligand interaction and molecular design, backed by $600M funding and collaborations with Novartis and J&J.
- Clinical trial director aiming to reduce trial size and predict patient responsePick: Atlas Discovery
Atlas Discovery's foundation models predict drug response from baseline biopsies (e.g., AUROC 0.76 for ustekinumab), enabling smarter trial design and power analysis.
- Pharma startup wanting to rescue a failed compoundPick: Atlas Discovery
Atlas Discovery includes drug rescue identification by modeling human clinical response, potentially repurposing compounds that failed in animal models.
- Research institution exploring digital biologyPick: Isomorphic Labs
Access to Isomorphic Labs' digital biology simulation at scale could accelerate basic research, though only through partner programs.
Frequently Asked Questions
Atlas Discovery vs Isomorphic Labs: which should you choose?
Isomorphic Labs is the pick for large pharma seeking end-to-end AI drug discovery with AlphaFold prestige and massive funding. Atlas Discovery is better for organizations focused on de-risking clinical trials via patient response predictions. Choose based on your bottleneck: molecule design or clinical success prediction.
What is the main difference between Isomorphic Labs and Atlas Discovery?
Isomorphic Labs focuses on early drug discovery (target identification, lead optimization) using AlphaFold AI. Atlas Discovery focuses on later-stage clinical trial success by predicting patient drug response from clinical data.
Can I use Isomorphic Labs as an individual researcher?
No. Isomorphic Labs operates exclusively through pharma partnerships, not offering standalone software or API access.
Does Atlas Discovery offer a self-service API?
No. Pricing is contact-based, and the platform is designed for R&D teams with clinical trial data access, not casual users.
Which company has more funding?
Isomorphic Labs raised $600M external investment in 2025 plus a Series B in 2026. Atlas Discovery is earlier stage (YC, Pear, Glasswing) with undisclosed amounts.
Which company uses AlphaFold?
Isomorphic Labs leverages the Nobel Prize-winning AlphaFold system from DeepMind as a core part of its Drug Design Engine.
What is ExpressionVAE?
Atlas Discovery's discrete-token encoding method for single-cell data, which outperforms continuous latent baselines by 3-20x on distributional metrics.
Has Atlas Discovery validated its model clinically?
Yes. It predicted response to ustekinumab in ulcerative colitis with an AUROC of 0.76 from baseline biopsies alone.
Is Isomorphic Labs a public company?
No. It is privately funded, backed by DeepMind/Google parent Alphabet and external investors.
More Atlas Discovery or Isomorphic Labs comparisons
Angle and Isomorphic Labs serve completely different domains—Angle is a free, niche pose-measurement tool for fitness professionals, while Isomorphic Labs is an enterprise AI drug discovery platform f
These tools are polar opposites in audience and purpose. Ironclaw AI Vision is a free, offline-first PWA for individual fitness tracking with AI coaching and meal planning – ideal for privacy-consciou
Choose Ray if you need an adaptive, low-barrier AI personal trainer for flexible, voice-guided workouts — it's ideal for busy individuals wanting consistency without gym intimidation. Choose Isomorphi
Isomorphic Labs and Swimio serve completely different worlds: one is a high-stakes pharma AI platform for billion-dollar drug programs, the other a consumer fitness app for swimmers. Choose based on y
MediSphere and Isomorphic Labs serve completely different healthcare verticals. Choose MediSphere if you run a small clinic needing AI-powered administration, no-show prediction, and EHR. Choose Isomo
These tools serve completely different markets. CalBye is a consumer nutrition app for individuals wanting effortless calorie tracking via photos, while Isomorphic Labs is an enterprise drug discovery
Explore each tool further
Browse these categories
One email a week — new tools, honest comparisons, no spam.
Last reviewed: July 3, 2026